Recent studies into retatruptide peptide demonstrate promising possibility for managing excess body and non-insulin dependent disease. The peptide, a dual activator of GLP-1 and GIP receptor, looks to provide improved weight loss and blood sugar control in contrast to existing treatments. Additional research efforts are needed to fully determine it